|
mpact of Valsartan on clinical outcome in obese hypertensive patient
|
|
| Author:
|
MSC. Y, PROF. DR. SAFFA A KHUDAIR, ASST. PROF. DR. HUSSEIN A SAHIB, PROF. DR. BASIM I MUHAMMED, NAJAH R. HADI
|
| Abstract:
|
Obesity and its associated cardiovascular, metabolic and renal disorders have quickly become a major threat to
global health. In obese individuals, studies have shown predominant high levels of plasma rennin activity,
angiotensinogen, Angiotensin II and aldosterone values. Angiotensin II type 1 receptor blockers constitute an
integral part in hypertension management and outcome improvement, however still there is inter-individual
variation in response to ARBs which can be attributed to obesity .Therefore, this study aimed to find out the effect
of obesity on angiotensin II type 1 receptor responsiveness in hypertensive patient treated with valsartan. Study
accomplished by enrolling 96 individuals(males and females) aged between 24-65 years, of Arab ancestry diagnosed
with essential hypertension were recruited by the specialist physician of Al-Sader teaching hospital in Najaf
governorate and Al-Diwaniyah teaching hospital at Al-Diwaniyah governorate. A mean dose of 110.8mg of
valsartan was administered for 3 weeks as a monotherapy, blood pressure was measured before and 3 weeks after
treatment. Height, weight, hip circumference, waist circumference, leptin level were measured. The subjects were
classified (depending on BMI) into two group, overweight/obese patient (whose BMI=25) 84 patients and normal
weight patient 12 patients (whose BMI less than25). The mean Systolic blood pressure at baseline was 173.5417
±1.75675 and the mean diastolic blood pressure at baseline was 109.7604 ±1.03785. Valsartan (mean dose 110.8
mg) significantly (p value 0.05) reduced the systolic blood pressure to a mean of 139.4271±1.19591 and mean
diastolic blood pressure to a mean of 88.6979 ±0.92256.compare to leptin level is higher in over weight\obese than
in normal weight(2573.6 in normal weight,4226.7 in overweight\obese with p value 0.0001) can be conclude that
valsartan is effective in the treatment of hypertensive obese patients it act by blocking angiotensin II type 1
receptor (involved in pathogenesis of obesity and hypertension). Large sample size, multi center cities and Include
large number of normal weight hypertensive patient were required.
|
| Keyword:
|
Valsartan, clinical outcome, hypertensive patient
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.12.02.0167
|
| Download:
|
Request For Article
|
|
|